Floatz logo

Davunetide

Mild Cognitive Impairment

Allon Therapeuticsprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
73/ 100

Competitive context

150 Active assets in the Mild Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Oxybutynin
University of Alberta
Phase 4BBB
LEVODOPA
Vanderbilt University Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Davunetide is also rated in:

schizophreniaDormant
CCC
Indicative ·
51 / 100
View asset →
tauopathyDormant
CC
Indicative ·
47 / 100
View asset →
progressive supranuclear palsyDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →